NIKE, Inc. is using a One Piece partnership to gauge digital demand. The collection debuts as the sportswear company moves to boost traffic while avoiding widespread markdowns.
The One Piece drop matters most as a SNKRS traffic and full-price sell-through test.
Watch inventory duration, app ranking, resale premium and markdowns—not search volume alone.
| Marker | Target | vs. close |
|---|---|---|
| JPM / Wells | $40 | -1.8% |
| Median | $47 | +15.3% |
| Average | $50.66 | +24.3% |
| Bernstein | $68 | +66.9% |
Bull case: quick full-price sell-through would support Nike's effort to rebuild scarcity and digital engagement. Bear case: a tiny allocation can sell out without improving broad demand. JD Sports' 6.8% North American comparable-sales fall keeps the recovery bar high.
One affected aircraft equals 3.23% of the A330-300 subfleet and 0.10% of Delta’s mainline fleet. A330-300 average age: 16.9 years at Dec. 31, 2025.
| 2Q26 adjusted metric | Result |
|---|---|
| Operating revenue | $17.7B |
| Operating margin | 8.8% |
| EPS | $1.56 |
| FY26 EPS guide | $6.50–$7.50 |
| FY26 FCF guide | $3B–$4B |
| Analyst | Firm | Rating | Target | Date |
|---|---|---|---|---|
| Sheila Kahyaoglu | Jefferies | Buy | $110 | Aug. 21 |
| Christian Wetherbee | Wells Fargo | Buy | $105 | Aug. 20 |
| Jason Sum | DBS | Buy | $110 | Aug. 13 |
| John Godyn | Citi | Buy | $110 | Aug. 7 |
| Catherine O’Brien | Goldman Sachs | Buy | $116 | Aug. 3 |
| DAL | $82.48 | +0.08% |
| UAL | $113.57 | +0.35% |
| LUV | $40.71 | +0.82% |
| JBLU | $4.95 | +1.23% |
Friday Aug. 21 DAL volume: 5.1M shares versus a 6.8M 50-day average.
| Scenario | Likely investor read |
|---|---|
| Single-aircraft repair | Contained cost |
| Short subfleet checks | Schedule friction |
| Engine-wide directive | Material capacity risk |
| No follow-on action | Event fades |
| Channel | Estimate | Share |
|---|---|---|
| Buildings | COP24.5tn | 81.7% |
| Infrastructure | COP5.5tn | 18.3% |
| Insured loss | Low- to mid-single-digit US$bn | Large uninsured gap |
| Indicator | Reading | Date |
|---|---|---|
| Central-government deficit | 6.4% of GDP / COP117.8tn | 2025 |
| Gross government debt | 64.4% of GDP | 2025 |
| July CPI | 6.03% y/y | Aug. 10 release |
| 2026 growth forecast | 2.5% | July BanRep report |
| Q3 10Y yield model forecast | 12.04% | Aug. 24 update |
Base case: reconstruction raises local funding needs without triggering an immediate FX break. Bear case: damage revisions, aftershocks or transport outages weaken both bonds and peso.
| Window | Event | What matters |
|---|---|---|
| Next 1–2 weeks | Updated national damage inventory | Size and timing of the public share |
| Next financing announcement | World Bank and other multilateral drawdowns | Concessional funding versus domestic issuance |
| Aug. 31 | Banco de la República regular meeting | Any assessment of quake inflation and growth channels |
| Sep. 30 | Policy-rate meeting | Whether 12% carry survives reconstruction pressure |
Market data: August 24, 2026, 16:00 EDT close · Financial data: fiscal Q3 ended June 30, 2026
Payment networks set records while broad indexes fell. That relative strength is consistent with confidence in nominal consumer spending.
| Firm | View | Target |
|---|---|---|
| Bernstein | Buy | $450 |
| Goldman Sachs | Buy | $438 |
| Bank of America | Buy | $430 |
| Consensus | Strong Buy | $416.20 |
| DBS | Buy | $410 |
| Current close | — | $382.41 |
The record close validates Visa's double-digit operating growth, but it also consumes valuation room. The consensus target is only 8.84% above the stock. Further gains now depend more on earnings delivery or fresh target increases than on simple multiple recovery.
Risk monitor: A consumer slowdown would reduce payment volume. Merchant-fee regulation could pressure revenue yields. Real-time payments and stablecoins could raise competitive intensity. A drop below recent volume growth or unchanged analyst targets would weaken the record-high setup.
Sources: Visa fiscal Q3 2026 SEC-filed earnings release; MarketWatch closing report dated August 24, 2026; StockAnalysis analyst forecast page checked August 24, 2026. Calculations use the $382.41 official close.
North American beverage sales rose, yet fewer units moved. The limited tropical launch gives PepsiCo a short, multi-channel test of whether innovation can rebuild volume.
Revenue reached $7.243 billion from $6.796 billion. The launch matters only if trial sales help narrow the unit decline.
PEP beat the index but lagged three listed beverage peers.
| P/E ratio | 18.98× |
| Dividend yield | 4.09% |
| Beta | 0.35 |
| 52-week range | $133.73–$171.48 |
| Below 52-week high | 15.6% |
The dividend cushions execution risk, but the stock still needs volume proof.
| Signal | Why it matters |
|---|---|
| Repeat purchases | Separates durable demand from launch-week trial. |
| Zero-sugar mix | Could lift relevance without leaning on full-sugar volume. |
| PBNA units | Next quarter must show whether the 4% decline moderates. |
| Organic sales | Management targets 2%–4% growth for 2026. |
PepsiCo does not publish Mountain Dew or SKU-level revenue. The launch is temporary. Fast trial can fade before repeat demand appears, while category volume remains weak.
Conclusion: useful demand experiment, not a standalone earnings forecast.
About 91% of the gross weekly increase came from repricing the previous ETH balance, not buying more tokens.
| ETH move | ETH price | Est. gross holdings |
|---|---|---|
| −10% | $2,196 | $13.47B |
| Reference | $2,440 | $14.90B |
| +10% | $2,684 | $16.33B |
Every $100 ETH move changes gross value by roughly $584.8 million. A 2% ETH move is about $285 million.
| Firm / source | View | Target |
|---|---|---|
| Cantor Fitzgerald | Overweight | $30.30 |
| B. Riley | Buy | $25.00 |
| S&P Global poll | Strong Buy | $31.87 avg. |
Latest cited updates were July 1–16, 2026. The small coverage base can lag a fast ETH move.
ETH rises, staking yield holds, and ETH per diluted share keeps increasing.
Separate token-price gains from value created through purchases and capital allocation.
Gross holdings ignore liabilities, taxes, dilution, private marks and staking constraints.
Sources: BitMine August 24 update, August 17 update, Yahoo Finance, Benzinga, StockAnalysis/S&P Global. Sensitivities are preliminary calculations, not company guidance.
FX dashboard · Canadian dollar
Market snapshot: August 24, 2026, 18:40 EDT. Currency figures reflect late Monday trading and the latest cited reports; forecast figures are dated August 12, 2026.
USD/CAD
1.385
Late trade, Aug. 24 EDT
CAD/USD
$0.722
About 72.2 U.S. cents
CAD daily move
−0.5%
Approximate, Aug. 24
Q3 bank average
1.40
About 1.1% above spot
New U.S. duty
50%
Roughly C$28bn of goods
| Scenario | USD/CAD zone | Signal |
|---|---|---|
| Talks restart; exemptions widen | 1.37–1.38 | CAD relief |
| Duties hold; limited escalation | 1.38–1.40 | Range |
| Retaliation broadens | 1.40–1.42 | CAD risk |
Scenario bands are analytical ranges, not point forecasts. The published August forecast range is 1.38–1.42.
| Forecaster | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Five-bank average | 1.40 | 1.38 | 1.36 |
| National Bank | 1.40 | 1.37 | 1.35 |
| TD | 1.37 | 1.35 | 1.33 |
| Desjardins | 1.42 | 1.40 | 1.38 |
| BMO | 1.41 | 1.40 | 1.39 |
| CIBC | 1.40 | 1.37 | 1.36 |
A contained M5.9 disruption meets a much larger Tokyo insurance tail risk.
Snapshot: 25 Aug 2026, 05:42 JST • Tokyo cash market closed; latest futures 24 Aug, 22:00 JST
Interpretation: semiconductor-heavy Nikkei weakness contrasted with positive broad-market breadth. Reports pointed to chip positioning and higher yields, not earthquake liquidation.
| Epicentre | Southern Ibaraki |
| Depth | ~70 km |
| Max intensity | Lower 5, JMA scale |
| Tsunami | None |
| Nuclear anomalies | None reported |
| Aftershock window | About one week |
| Channel | Current reading | Sensitivity |
|---|---|---|
| Transport | Brief rail delays; Shinkansen normal | |
| Utilities | Local outages; one Tokyo pipe repaired | |
| Industrial supply | No broad shutdowns reported | |
| Insurance | Claims likely local; tail exposure high | |
| Financial plumbing | BoJ backup plans rehearsed |
Sensitivity bars are qualitative risk channels, not loss forecasts.
Calculated with the standard magnitude-energy relationship: 101.5×(7.1−5.9). This is a physical comparison, not a damage estimate.
Swiss Re's insured-loss scenario for a severe Tokyo-region earthquake. It is not an estimate for the current M5.9 event.
The current market calm reflects limited observed damage. It does not remove Tokyo's concentration risk.
| Signal | Contained case | Escalation case |
|---|---|---|
| Aftershocks | No stronger event | Similar or stronger shaking |
| Infrastructure | Services normalized | New rail, utility or data-centre outages |
| Equities | TOPIX breadth stays positive | Broad selling replaces index-only weakness |
| Credit/insurance | Local claims | Material loss disclosures or reserve changes |
AP event report
Kabutan close
OSE futures snapshot
Swiss Re scenario
BoJ continuity planning
PlayStation's operating margin rose to 21.6% while monthly active users reached 125 million. A digital-first model can reduce physical distribution friction and deepen recurring platform spend. Sony's ADR has stayed above both key moving averages.
Quarterly playtime already fell 4%. If the boycott turns into weaker store purchases, subscriptions or next-console demand, the margin benefit may arrive with a smaller user base. Tariff refunds and foreign exchange also boosted the latest profit gain.
SALESFORCE · NYSE:CRM · EARNINGS SETUP
Options imply a 7% move after Wednesday’s report. Consensus revenue is only $10 million above the midpoint of management’s range, leaving cRPO and underlying growth to decide the direction.
The stock recovered 10.0% from August 17’s close. Monday’s verified range was $207.39–$213.17.
| Measure | Company guide | Consensus | Read-through |
|---|---|---|---|
| Revenue | $11.27B–$11.35B | $11.32B–$11.33B | Near guide ceiling |
| Adjusted EPS | $3.25–$3.27 | $3.27–$3.28 | At/above guide ceiling |
| cRPO growth | ≈14%; 13% CC | >13% | Acceleration test |
| FY2027 revenue | $45.9B–$46.2B | Watch revision | Includes ≈3 pts Informatica |
Q1 revenue was $11.133B. Removing the disclosed $444M Informatica contribution leaves $10.689B against $9.829B one year earlier.
The earnings question is whether those products lift core growth, rather than merely improving the reported mix.
Bull casecRPO at or above 14%, clean core acceleration, maintained 34.3% non-GAAP margin.
MiddleHeadline beat, but growth relies on Informatica and guidance barely moves.
Bear casecRPO below 13%, weaker organic outlook or cash-flow guide cut.
UnitedHealth is sacrificing membership to restore margins. The second-quarter medical care ratio improved 270 basis points, but commercial medical-cost growth remains modestly above 11%. The stock's forward multiple therefore prices a recovery that is real, but not yet complete.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $112.0B | $111.6B | +0.4% |
| Operating earnings | $8.0B | $5.2B | +54% |
| Medical care ratio | 86.7% | 89.4% | −270 bp |
| UnitedHealthcare margin | 4.6% | 2.4% | +220 bp |
| Optum margin | 6.2% | 4.6% | +160 bp |
| UHC membership | 48.5M | — | −525K q/q |
| 2026 measure | Jan. 27 | July 16 | Signal |
|---|---|---|---|
| Adjusted EPS | >$17.75 | $19.50–$20.00 | Raised |
| Operating earnings | >$24.0B | >$25.45B | Raised |
| Cash from operations | >$18.0B | ~$24.0B | Raised |
| Share repurchases | ~$2.5B | ≥$5.0B | Doubled |
| Medical care ratio | 88.8% ±50 bp | 88.1% ±25 bp | Improved |
| Firm | Date | Rating | Target |
|---|---|---|---|
| JPMorgan | Jul. 21 | Overweight | $516 |
| Mizuho | Jul. 21 | Outperform | $493 |
| BofA Securities | Jul. 20 | Buy | $512 |
| Wells Fargo | Jul. 2026 | Overweight | $526 |
| Company | Price | Day | Trailing P/E |
|---|---|---|---|
| UnitedHealth | $399.06 | +2.29% | 25.6× |
| Elevance Health | $402.56 | +0.50% | 17.8× |
| CVS Health | $93.31 | +0.31% | 24.6× |
| The Cigna Group | $278.73 | +0.44% | 11.5× |
| Humana | $385.47 | +1.74% | 36.4× |
| Risk | Transmission | Dashboard trigger |
|---|---|---|
| Commercial medical costs | Claims growth outruns pricing and delays margin recovery. | Trend stays above 11% into 2027. |
| Reserve quality | Q2 MCR benefited from $860M of favorable prior-period development. | Development fades or reverses. |
| Government programs | Medicare and Medicaid rate changes pressure margins or membership. | Reimbursement trails care-cost inflation. |
| Optum execution | A slower recovery weakens the earnings bridge supporting the multiple. | Optum margin stalls below the 6.2% Q2 level. |
| Firm | Rating | Target |
|---|---|---|
| Jefferies | Buy | $120 |
| Raymond James | Buy | $130 |
| Deutsche Bank | Hold | $113 |
| Signal | What it means | Next check |
|---|---|---|
| CPI-W | The statutory COLA input; July is only one of three deciding months. | August CPI — Sept. 11 |
| Gross benefit | A 3.5% midpoint implies about $73 more monthly for an average retired worker. | Official COLA — Oct. 14 |
| Net benefit | Medicare Part B premiums can absorb part of the headline increase. | Premium notice — autumn |
| Retail read-through | Helpful for nominal budgets, but food, fuel and rent can take the cash first. | WMT Q3 — next earnings |
| Broker | View | Target | Date |
|---|---|---|---|
| Bernstein SocGen | BUY | $3,000 | Aug 17 |
| Citi | BUY | $2,100 | Aug 14 |
| Mizuho | BUY | $1,900 | Aug 14 |
| RBC Capital | HOLD | $1,600 | Aug 14 |
| Wells Fargo | HOLD | $1,550 | Aug 14 |
Tesla’s 2.98 million-vehicle action equals 11.2× its 2026 China retail sales through July.
Most remedies use warning labels and remote software, limiting workshop time and hardware expense.
July local deliveries fell 32.9% YoY to 27,249. Exports reached a record 66,330.
Monday’s move also reflects wider auto-sector pressure from new tariff threats. The recall should not be treated as the sole price catalyst.
| Firm | Call | Target |
|---|---|---|
| GLJ | Sell | $200 |
| Barclays | Hold | $370 |
| Wells Fargo | Sell | $130 |
| Morgan Stanley | Hold | $400 |
| DBS | Hold | $330 |
47-analyst consensus: Buy. Target range: $125–$600.
The stock opened below its August 20 launch-day close of $80.14. The completed-session tape does not support a post-launch $6 billion gain.
Market value rose $17.49B from August 17 to August 19. After the show launched, capitalization fell $2.62B through Friday.
Consensus: Buy · 51 analysts
| Firm | Call | Target |
|---|---|---|
| J.P. Morgan | Buy | $85 |
| BMO | Buy | $135 |
| DBS | Buy | $94 |
| Baird | Buy | $90 |
Bull case: fresh content supports retention, pricing and an ad business targeting about $3B in 2026 revenue.
Bear case: slower growth and limited title-level evidence leave investors paying about 23 times forward earnings without a clear engagement inflection.
The useful signal is the gap: Nasdaq 100 futures fell almost three times as much as Dow futures. Nvidia earnings and Wednesday's inflation data now carry more weight than the blue-chip headline.
Macro data lands first. A hotter reading would raise the hurdle for tech valuations.
The company call begins at 17:00 EDT. Guidance is likely to matter more than the headline beat.
Markets want a policy framework. Less guidance could leave long yields in control.
| Analyst | Firm | Call | Target | Aug. 24 action |
|---|---|---|---|---|
| Harlan Sur | J.P. Morgan | Buy | $280 | Reiterated |
| John Vinh | KeyBanc | Buy | $330 | Maintained |
| C.J. Muse | Cantor Fitzgerald | Buy | $350 | Maintained |
| Kevin Cassidy | Rosenblatt Securities | Buy | $325 | Maintained |
| Vijay Rakesh | Mizuho Securities | Buy | Not listed | Reiterated |
| Program | Status | Next event |
|---|---|---|
| GPS / REGAL Phase 3 | 78 of 80 events as of May 11 | 80th event → final analysis |
| SLS009 frontline AML | 28 of 80 patients enrolled | Topline Q4 2026 |
| SLS009 pancreatic | Preclinical | Conference data |
| Consensus | BUY |
| Average target | $32.50 |
| Maxim | $30 |
| Alliance Global | $35 |
NIO Inc. · overseas optionality versus Chinese operating leverage
The stock recovered Friday but remained 42.3% below its $8.02 52-week high. Monday's premarket reversal returned focus to execution risk.
NIO scopes include Firefly where reported. The scale difference makes Europe a strategic signal, not a near-term earnings driver.
| Measure | Q1'26 | Q4'25 | Q1'25 |
|---|---|---|---|
| Revenue | 25.53bn | 34.65bn | 12.03bn |
| Gross margin | 19.0% | 17.5% | 7.6% |
| Vehicle margin | 18.8% | 18.1% | 10.2% |
| Adj. operating P/(L) | 66.8m | 1.25bn | −5.95bn |
| Cash & liquid funds | 48.2bn | 45.9bn | — |
Q2 deliveries were 107,658, below NIO's 110,000–115,000 guidance. September 1 will reveal the margin cost.
| What to watch | Bull case | Bear case |
|---|---|---|
| Vehicle margin | Holds near 18.8% | Discounting breaks the trend |
| Cash conversion | Fourth positive operating-cash quarter | Working-capital reversal |
| August deliveries | Reaccelerate above July's 35,934 | Sequential decline persists |
| Europe plan | New platform timetable or distributors | Old stock lasts into late 2027 |
NASDAQ: MU · Memory cycle stress test
21 Aug, 16:00 EDT
Reported 24 Aug, 05:26 EDT
17–21 Aug closes
+56.7% vs last close
Closes: $1,011.75 · $940.76 · $937.11 · $974.33 · $966.78
Peer capital-return disappointment hit a crowded memory trade. New Chinese funding adds a longer-dated supply question.
Micron fiscal Q3 2026. Bars use revenue as the scale anchor, except margin.
| Firm | View | Target |
|---|---|---|
| UBS | Buy | $1,625 |
| BofA | Buy | $1,550 |
| New Street | Buy | $1,250 |
| Consensus | Strong Buy | $1,515 |
47 analysts: 34 Strong Buy, 9 Buy, 4 Hold, 0 Sell.
Micron's earnings case remains strong. The new risk is expectation density: record margins, sustained AI spending and disciplined industry supply are all embedded in the bullish consensus.
Market data: Nasdaq/StockAnalysis and MarketWatch, captured 24 Aug 2026 at 05:26 EDT. Financials: Micron fiscal Q3 2026. Analyst targets: S&P Global/Investing.com snapshot. Premarket data is indicative and may move sharply before the open.
Consensus: Strong Buy. Twenty-seven of 28 recommendations are Buy or Strong Buy.
The market punished loss of marketing control, then bought the schedule. Thursday's August 27 extended preview is the next measurable checkpoint. Engagement and a firm November 19 release date matter more than the leaked clips themselves.
